Skip to main content
. Author manuscript; available in PMC: 2014 Jan 13.
Published in final edited form as: Int J Oncol. 2011 Jun 16;39(4):891–898. doi: 10.3892/ijo.2011.1085

Figure 2.

Figure 2

Cisplatin plus TRAIL treatment decreases cancer stem cells. The effect of cisplatin, TRAIL, cisplatin plus TRAIL, PARP inhibitors AZD2881, BSI-20, paclitaxel and docetaxel treatment on ALDEfluor+ (CSCs) population was analyzed after 24 h treatment. The cell percentage numbers for ALDH-positive cells are indicated in the bottom right of each histogram. Maximum decrease in ALDH-positive population was seen in cisplatin plus TRAIL-treated group compared to control in both triple negative cell lines CRL2333 (A) and in MDA-MB-468 cells (B). (C). Cisplatin plus TRAIL-induces cell death in both tumor and cancer stem cells. In general cancer stem cells are resistant to traditional chemotherapy. However, combination of cisplatin plus TRAIL treatment significantly inhibits both tumor cells (white bars) and cancer stem cells (black bars).